Slide background

FROM CANCER RESEARCH TO CURE

Slide background

IMMUNO-ONCOLOGY IS AN AREA OF STRENGTH

Slide background

OUR VISION IS TO IMPROVE THE LIVES OF CANCER PATIENTS

Slide background

OSLO CANCER CLUSTER INNOVATION PARK

PHYSICAL EMBODIMENT OF THE CANCER CLUSTER

Videos

LATEST NEWS

Targovax ASA moves share listing to Oslo Børs

Oslo, Norway, 23 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. The Company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange.

Targovax ASA: Annual Report 2016

On 15 March 2017, the Board of Directors of Targovax ASA approved the financial statements for 2016 for issuance, subject to approval by the Annual General meeting on April 5, 2017.

Tweets

MEMBERS OF OSLO CANCER CLUSTER